Bright Light Therapy for Nonseasonal Depressive Disorders: A Systematic Review and Meta-Analysis.

Autor:	Menegaz de Almeida A; Federal University of Mato Grosso, Sinop, Brazil., Aquino de Moraes FC; Federal University of Pará, Belém, Brazil., Cavalcanti Souza ME; University of Pernambuco, Recife, Brazil., Cavalcanti Orestes Cardoso JH; University of Pernambuco, Recife, Brazil., Tamashiro F; Buenos Aires University, Buenos Aires, Argentina., Miranda C; Bahiana School of Medicine, Salvador, Brazil., Fernandes L; Afya School of Medical Sciences, Abaetuba, Pará, Brazil., Kreuz M; Lutheran University of Brazil, Canoas, Rio Grande do Sul, Brazil., Alves Kelly F; Dante Pazzanese Institute of Cardiology, Sao Paulo, Brazil.
Jazyk:	angličtina
Zdroj:	JAMA psychiatry [JAMA Psychiatry] 2024 Oct 02. Date of Electronic Publication: 2024 Oct 02.
DOI:	10.1001/jamapsychiatry.2024.2871
Abstrakt:	Importance: Seasonal humor disorders are prone to have a link with daylight exposure. However, the effect of external light on nonseasonal disorders remains unclear. Evidence is lacking for the validity of bright light therapy (BLT) as an adjunctive treatment for these patients. Objective: To assess BLT effectiveness as an adjunctive treatment for nonseasonal depressive disorders. Data Sources: In March 2024, a comprehensive search was performed of publications in the MEDLINE, Embase, and Cochrane databases for randomized clinical trials (RCTs) evaluating BLT effects in patients with nonseasonal depression. Study Selection: RCTs published since 2000 were eligible. Comparisons between BLT and dim red light or antidepressant monotherapy alone were considered for inclusion. Data Extraction and Synthesis: Using the systematic review approach on RCTs published from January 1, 2000, through March 25, 2024, differences between patients treated with and without BLT were estimated using the Mantel-Haenszel method; heterogeneity was assessed using I2 statistics. Main Outcomes and Measures: Remission of symptoms, response to treatment rates, and depression scales were assessed. Results: In this systematic review and meta-analysis of 11 unique trials with data from 858 patients (649 female [75.6%]), statistically significant better remission and response rates were found in the BLT group (remission: 40.7% vs 23.5%; odds ratio [OR], 2.42; 95% CI, 1.50-3.91; P <.001; I2 = 21%; response: 60.4% vs 38.6%; OR, 2.34; 95% CI, 1.46-3.75; P <.001; I2 = 41%). With BLT, subgroup analysis based on follow-up times also showed better remission (<4 weeks: 27.4% vs 9.2%; OR, 3.59; 95% CI, 1.45-8.88; P = .005; I2 = 0% and >4 weeks: 46.6% vs 29.1%; OR, 2.18; 95% CI, 1.19-4.00; P = .01; I2 = 47%) and response (<4 weeks: 55.6% vs 27.4%; OR, 3.65; 95% CI, 1.81-7.33; P <.001; I2 = 35% and >4 weeks: 63.0% vs 44.9%; OR, 1.79; 95% CI, 1.01-3.17; P = .04; I2 = 32%) rates. Conclusions and Relevance: Results of this systematic review and meta-analysis reveal that BLT was an effective adjunctive treatment for nonseasonal depressive disorders. Additionally, results suggest that BLT may improve the response time to the initial treatment.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu